Central hypothyroidism is a form of hypothyroidism caused by defective stimulation of the thyroid gland by the hypothalamic-pituitary axis, resulting in inadequate thyroid hormone production despite a thyroid gland that is often structurally intact. Unlike primary hypothyroidism, in which the disorder originates within the thyroid gland and is characterized by a compensatory increase in thyroid-stimulating hormone (TSH), in central hypothyroidism the thyrotropic signal is reduced or biologically ineffective. TSH may be low, normal, or only mildly elevated, but remains inappropriate relative to a reduced level of free thyroxine (FT4). This makes diagnosis more complex because screening based on TSH alone may fail to identify the condition.
From a clinical perspective, central hypothyroidism occurs predominantly in the setting of pituitary or hypothalamic disorders, is frequently associated with other hormonal deficiencies, and may develop after sellar surgery, cranial radiotherapy, infiltrative lesions, or inflammatory processes, including conditions related to cancer immunotherapy. Management requires an axis-centered approach. Any possible central adrenal insufficiency must first be excluded or treated, after which replacement therapy with levothyroxine is initiated using FT4 as the monitoring parameter, generally targeting the upper half of the reference interval.
Central hypothyroidism is considered rare compared with primary hypothyroidism, and its epidemiology depends largely on the prevalence of disorders affecting the hypothalamic-pituitary unit, the long-term survival of patients treated for intracranial tumors, and the intensity of endocrine monitoring in high-risk settings. In clinical practice, its frequency is therefore driven by specialist settings such as pituitary disease clinics, postoperative follow-up after sellar surgery, follow-up after cranial radiotherapy, and oncology pathways involving immunotherapy. In these settings, central hypothyroidism often coexists with deficiencies involving other hormonal axes, producing hypopituitarism of variable extent and severity.
The most relevant risk factors include space-occupying lesions of the sella turcica and parasellar region. Pituitary macroadenomas and suprasellar lesions may impair thyrotropic function through compression of the remaining functional tissue, disruption of vascular supply, and functional disconnection of hypothalamic signaling caused by involvement of the pituitary stalk. Craniopharyngiomas, parasellar meningiomas, and tumors of the hypothalamic region carry a particularly high risk of hypothalamic-pituitary dysfunction, often involving multiple endocrine axes.
Iatrogenic causes represent a major category. Pituitary surgery may produce transient or permanent thyrotropic deficiency depending on the underlying disease, the extent of resection, and the preoperative functional reserve. Radiotherapy involving the sellar region or the brain, whether conventional or stereotactic, is associated with progressive hypothalamic-pituitary dysfunction that may emerge even several years later. Prolonged endocrine follow-up with periodic assessment of thyroid function and the other hormonal axes is therefore required.
An increasingly important risk factor is cancer treatment with immune checkpoint inhibitors. In this setting, pituitary dysfunction may present as hypophysitis with deficiencies of pituitary hormones, most commonly affecting the corticotropic axis, although thyrotropic function may also be involved. Diagnosis requires particular attention because symptoms such as fatigue, nausea, and reduced performance may be attributed to the underlying cancer or to nonspecific treatment-related effects, while part of the clinical picture may result from a correctable central hormonal deficiency.
Other risk factors include traumatic brain injury and subarachnoid hemorrhage, conditions in which post-event pituitary dysfunction may be underestimated when no structured surveillance pathway is available. Infiltrative and inflammatory disorders, including sarcoidosis, histiocytosis, hemochromatosis, and immunoglobulin G4-related diseases, increase the likelihood of multiple hormonal deficiencies and may involve the pituitary gland or hypothalamus with a subacute or chronic course.
In children and young adults, central hypothyroidism may be related to congenital or genetic disorders, often in the setting of combined pituitary hormone deficiencies. In these cases, a suggestive neonatal history, impaired growth, and symptoms compatible with hypothyroidism, particularly when associated with hypoglycemia or other signs of pituitary hormone deficiency, represent a high-risk clinical setting requiring prompt diagnosis to prevent adverse effects on neurodevelopment and growth.
Central hypothyroidism results from impaired production, secretion, or biological activity of TSH and, upstream, from reduced hypothalamic stimulation mediated by thyrotropin-releasing hormone (TRH). Under physiological conditions, thyrotropin is a glycoprotein hormone whose biological function depends not only on its circulating concentration but also on qualitative characteristics, particularly glycosylation, biological activity, and secretory dynamics. In hypothalamic-pituitary disorders, TSH may be quantitatively reduced or may appear reassuringly normal despite being inadequate relative to the FT4 level. It may also be qualitatively less effective, resulting in insufficient thyroid stimulation and reduced production of T4 and T3.
From an etiologic perspective, the causes may be classified as compressive, infiltrative, inflammatory, vascular, iatrogenic, or genetic. Compressive causes include adenomas and parasellar tumors that reduce the amount of functioning tissue or disrupt the hypothalamic-pituitary connection. Infiltrative disorders, such as sarcoidosis and histiocytosis, progressively replace the parenchyma with inflammatory or fibrotic tissue and often present as multisystem disease. Inflammatory causes include several forms of hypophysitis, including immune-related forms, in which thyrotropic deficiency may coexist with other central endocrine deficiencies.
The pathophysiology of central hypothyroidism is distinctive because TSH has limited reliability as both a marker and a therapeutic target. In primary hypothyroidism, TSH reflects pituitary exposure to thyroid hormones and is an effective indicator of replacement adequacy. In central hypothyroidism, the pituitary gland is part of the disease process, and TSH may therefore fail to reflect whether FT4 replacement is adequate. A normal TSH does not exclude tissue thyroid hormone deficiency, and a low TSH during treatment does not necessarily indicate overtreatment. The most useful parameter is consequently FT4, interpreted in the clinical context and with awareness of the analytical limitations of laboratory methods during systemic illness.
At the systemic level, thyroid hormone deficiency produces the typical effects of hypothyroidism on metabolism, thermogenesis, cardiovascular function, and neurocognitive performance. In patients with concurrent pituitary disease, however, the pathophysiology becomes systemic because the coexistence of deficiencies involving growth hormone (GH), gonadotropins, or adrenocorticotropic hormone (ACTH) may intensify fatigue, weight changes, dyslipidemia, and frailty, making the presentation less specific. Treatment of other hormonal axes may also alter thyroid hormone balance. GH therapy may affect peripheral conversion and the availability of T4 and T3, requiring levothyroxine dose adjustments in some patients.
A critical mechanism concerns the sequence of treatment in patients with multiple hormonal deficiencies. Starting levothyroxine in a patient with unrecognized central adrenal insufficiency may increase glucocorticoid requirements and precipitate decompensation because it accelerates cortisol metabolism and increases systemic metabolic demand. This interaction is not merely an operational consideration but a fundamental pathophysiological factor that directly affects safety and prognosis. The corticotropic axis must therefore be assessed before thyroid hormone replacement is initiated.
In congenital or genetic forms, the defect may involve pituitary development or the synthesis of TSH, TRH, or receptors involved in their regulation. In these cases, inadequate thyroid stimulation is present from birth or early childhood, with implications for neurodevelopment and growth. The pathophysiological consequences are therefore closely related to the timing of diagnosis and the speed of correction because early exposure to inadequate thyroid hormone levels may cause permanent consequences when treatment is delayed.
The clinical presentation of central hypothyroidism is often less recognizable than that of primary hypothyroidism because symptoms may be subtle, masked by the underlying pituitary disorder, or confused with other concurrent endocrine deficiencies. In many cases, the presentation is insidious and chronic, with a progressive decline in performance, increasing fatigue, and deterioration in general well-being. In other cases, central hypothyroidism develops after an iatrogenic or inflammatory event, such as sellar surgery or hypophysitis, within an already complex clinical course that requires careful temporal assessment.
During history-taking, patients may report fatigue, psychomotor slowing, somnolence, impaired concentration, and reduced working memory. Cold intolerance, weight gain that is not necessarily marked, constipation, and dry skin may occur. The voice may become hoarser, the skin colder and drier, and exercise tolerance may decline, with easy fatigability. In many individuals, these symptoms are attributed to stress, depression, or chronic illness, particularly when cardiovascular, oncologic, or neurological comorbidities coexist.
On physical examination, findings may include bradycardia, reduced reflex responsiveness with delayed relaxation, dry skin, and, in more pronounced cases, reduced facial expression and mild edema. In many patients, however, signs are modest or absent. In patients with sellar lesions, the clinical picture may include headache, visual field defects, and other mass-related symptoms. In combined pituitary hormone deficiencies, decreased libido, amenorrhea or infertility, signs of adrenal insufficiency, and manifestations related to GH deficiency may coexist, making endocrine assessment an exercise in integrating common symptoms with axis-specific findings.
From a cardiovascular and metabolic perspective, central hypothyroidism may be associated with dyslipidemia characterized by increased low-density lipoprotein (LDL) cholesterol, reduced aerobic capacity, and increased vascular stiffness. These alterations may affect cardiovascular risk, particularly when hypothyroidism remains unrecognized or undertreated. Interpretation must nevertheless account for the possible contribution of hypogonadism, GH deficiency, diet, sedentary behavior, and medications. The clinical value of an accurate diagnosis lies in the possibility of correcting part of these metabolic abnormalities through appropriate thyroid hormone replacement while avoiding overtreatment.
In children, clinical manifestations may include impaired growth, delayed skeletal maturation, reduced growth velocity, and, in early-onset cases, adverse neurodevelopmental consequences. In neonates and infants, signs may be nonspecific, and screening based solely on TSH may fail to detect the condition. In this setting, hypoglycemia, prolonged jaundice, feeding difficulties, or signs suggestive of combined pituitary hormone deficiencies should increase clinical suspicion and prompt a complete assessment including FT4.
In more severe or neglected cases, hypothyroidism may progress to systemic complications, including cognitive deterioration, hypoventilation, effusions, and functional decompensation. Although myxedema coma is more typical of severe primary hypothyroidism, progression to advanced disease is possible when central hypothyroidism remains unrecognized, particularly in frail patients and during intercurrent illnesses. Clinical vigilance must therefore remain high in at-risk settings even when TSH does not clearly suggest the diagnosis.
Central hypothyroidism should be suspected when symptoms compatible with hypothyroidism develop in a patient with a biological or iatrogenic risk of hypothalamic-pituitary disease, or when laboratory tests show a low FT4 or an FT4 near the lower limit of normal together with a TSH that is not elevated or is only mildly increased. This pattern is inappropriate and should be regarded as a potential sign of central dysfunction because, under normal conditions, a reduction in FT4 should induce an increase in TSH. Clinicians must remember that a TSH within the reference range does not exclude central hypothyroidism and that a screening strategy based exclusively on TSH may fail precisely in patients in whom diagnosis is most important.
Suspicion is particularly high in patients with a history of pituitary adenoma, craniopharyngioma, or other sellar lesions, in patients who have undergone surgery involving the pituitary region, and in those who have received cranial radiotherapy. In these cases, the development of worsening fatigue, cold intolerance, weight gain, bradycardia, or deterioration of the lipid profile should prompt simultaneous measurement of FT4 and TSH, with interpretation within the overall endocrine context.
Suspicion should also be high when signs of other pituitary hormone deficiencies coexist, particularly findings suggestive of central adrenal insufficiency or hypogonadotropic hypogonadism. Hypotension, nausea, unintentional weight loss, or unexplained hypoglycemia should lead to priority assessment of the corticotropic axis because coexisting adrenal insufficiency alters the urgency, diagnostic testing, and safety of thyroid hormone replacement. Amenorrhea, reduced libido, and infertility associated with symptoms of hypothyroidism also increase the likelihood of multiaxial pituitary involvement.
In oncology, the development of marked fatigue, slowing, and symptoms compatible with hypothyroidism in patients treated with immune checkpoint inhibitors should prompt evaluation not only for primary thyroid dysfunction, which is common in these patients, but also for pituitary involvement causing central hypothyroidism, particularly when FT4 is reduced without an increase in TSH.
In pediatrics and neonatology, suspicion should be maintained when signs of pituitary or hypothalamic dysfunction are present, including recurrent hypoglycemia, micropenis, cholestasis, midline defects, or a suggestive family history. In these circumstances, TSH measurement alone may be insufficient, and FT4 assessment is crucial to avoid missing a diagnosis with major implications for neurodevelopment.
Central hypothyroidism should therefore be suspected whenever reduced FT4 is not accompanied by an appropriate increase in TSH and in all clinical contexts associated with a risk of hypothalamic-pituitary dysfunction, because early identification changes management, therapeutic safety, and prognosis.
The diagnosis of central hypothyroidism is based on the demonstration of a low FT4 associated with a low, normal, or only mildly elevated TSH, in the absence of an appropriate thyrotropic response. This pattern should be confirmed by repeating the tests, particularly when results are borderline, and interpreted in consideration of preanalytical variables, medications, and intercurrent conditions. During acute systemic illness, non-thyroidal illness syndrome may reduce FT4 and alter TSH, producing a biochemical pattern that mimics central hypothyroidism. Diagnosis therefore often requires temporal assessment, repeated testing under stable conditions, and integration with the clinical context.
Because TSH is less reliable, the diagnostic workup must prioritize FT4 and the physiological consistency of the overall pattern. Measurement of free triiodothyronine (FT3) may be useful in selected situations, but it is more susceptible to changes during systemic illness and does not independently establish the diagnosis. Analytical interference affecting FT4 measurement may occur in certain clinical settings. When results are inconsistent with the clinical picture or other laboratory findings, the test should be repeated and, when necessary, alternative analytical methods or a laboratory experienced in pituitary endocrinology should be used.
A fundamental step is evaluation of the hypothalamic-pituitary unit and investigation of associated hormonal deficiencies. Assessment must include at least the corticotropic axis because central adrenal insufficiency changes the urgency and safety of treatment. The gonadotropic and somatotropic axes should also be evaluated when clinically indicated. The objective is not only to identify central hypothyroidism but also to place it within the broader context of hypopituitarism and establish appropriate therapeutic priorities.
Imaging is an important component of the diagnostic pathway when central hypothyroidism is suspected or confirmed. Magnetic resonance imaging of the hypothalamic-pituitary region may identify adenomas, craniopharyngiomas, hypophysitis, infiltrative lesions, and abnormalities of the pituitary stalk. In patients who have undergone surgery or radiotherapy, imaging helps distinguish expected treatment-related changes from recurrence or progression. In immune-related conditions, imaging findings may vary and do not always correlate with the severity of hormonal deficiency. Diagnosis therefore remains primarily based on the integrated interpretation of biochemical and clinical findings.
In selected cases, dynamic tests such as the TRH stimulation test may provide information about thyrotropic reserve and may help distinguish hypothalamic from pituitary involvement, although their use is limited by availability and variability among protocols. In clinical practice, the combination of the biochemical pattern, clinical context, and imaging findings is usually sufficient to establish the diagnosis and initiate management.
The differential diagnosis includes atypical primary hypothyroidism, non-thyroidal illness, medications that suppress TSH, and conditions in which FT4 is falsely low or TSH is falsely normal. The diagnostic approach is based on physiological consistency and reproducibility. A persistently reduced FT4 associated with a non-elevated TSH, together with hypothalamic-pituitary disease or deficiencies involving other hormonal axes, makes the diagnosis highly probable and requires structured and timely management.
The classification of central hypothyroidism is clinically useful because it guides etiologic evaluation, risk assessment, and treatment strategy. A first distinction separates pituitary forms from hypothalamic forms. In pituitary forms, the primary defect is reduced TSH secretion. In hypothalamic forms, reduced TRH stimulation and disruption of central regulation predominate. This distinction may influence TSH characteristics, the response to dynamic testing, and the coexistence of autonomic dysfunction and altered energy regulation typical of hypothalamic involvement. In clinical practice, however, overlap is common, and management remains guided by FT4.
A second distinction separates isolated from combined forms. Isolated central hypothyroidism is less common and may occur in specific disorders, including certain forms of hypophysitis and some genetic conditions. More frequently, central hypothyroidism is part of hypopituitarism involving multiple axes. In this setting, overall severity also depends on the presence of central adrenal insufficiency, which represents the most critical deficiency because of its acute risks.
A third criterion distinguishes congenital from acquired forms. Congenital forms include defects of pituitary development and mutations affecting TSH production or function and its regulatory pathways. Acquired forms include adenomas, craniopharyngiomas, the consequences of surgery and radiotherapy, infiltrative lesions, and inflammatory processes, including immune-related conditions. This distinction is essential because it affects the timing of diagnosis, the consequences for growth and neurodevelopment, and the likelihood of functional recovery.
Severity may be assessed according to the degree of reduction in FT4 and the clinical impact. In mild forms, FT4 is near the lower limit of normal and symptoms may be modest or difficult to distinguish from other conditions. In more severe forms, FT4 is clearly reduced and clinical manifestations become more apparent, with cardiovascular, metabolic, and neurocognitive consequences. In patients with multiple deficiencies, severity must also account for overall frailty and interactions among hormonal axes because moderate hypothyroidism may produce greater consequences in the presence of other endocrine deficiencies or systemic disease.
A final practical classification concerns the course over time. Some patients develop progressive deficiency, particularly after radiotherapy or during growth of a sellar lesion, whereas others have stable dysfunction. In selected cases, especially after inflammatory events or surgery, partial recovery may occur. Planned endocrine reassessment under controlled conditions may therefore be appropriate, provided that clinical safety is ensured and management is supervised by experienced specialists.
Treatment of central hypothyroidism consists of replacement with levothyroxine, prescribed to restore adequate thyroid hormone availability within tissues and monitored using FT4 as the principal parameter. Because TSH is not a reliable therapeutic target, the practical objective is to maintain FT4 within the upper half of the reference interval, adjusting the dose according to clinical status, age, body weight, comorbidities, and concomitant therapies. International recommendations indicate that, in most adults with central hypothyroidism, the dose should be sufficient to achieve an upper-normal FT4 level while avoiding both undertreatment and iatrogenic excess.
Before levothyroxine is started, the corticotropic axis must be assessed and any central adrenal insufficiency must be treated because thyroid hormone replacement may increase glucocorticoid requirements and precipitate decompensation in patients without adequate glucocorticoid coverage. This principle is particularly important in hypopituitarism and in patients who have undergone surgery or developed hypophysitis. The treatment sequence directly affects safety and prognosis and must be an integral part of management.
The initial levothyroxine dose must be individualized. In adults who are not elderly and do not have cardiovascular disease, a weight-based dose may be used, followed by adjustments according to FT4 and the clinical response. In older patients or those with cardiovascular disease, treatment should begin cautiously with lower doses and gradual increases, while monitoring tolerance, heart rate, and symptoms of thyroid hormone excess. The objective is not rapid normalization but safe restoration of thyroid hormone balance, taking into account the frequent presence of comorbidities and multiple concomitant therapies.
Treatment must account for factors that influence absorption and bioavailability. Iron and calcium supplements, resins, certain gastric acid-suppressing therapies, and malabsorption disorders may reduce absorption and require dose adjustment or revision of administration timing. Hormonal therapies such as estrogens may alter binding proteins and influence interpretation of laboratory parameters, whereas pituitary replacement therapies such as GH may modify thyroid hormone balance and require reassessment of the levothyroxine dose during follow-up.
In special clinical settings, the strategy must be even more precise. During pregnancy, replacement must ensure adequate thyroid hormone availability, with more frequent monitoring and early dose adjustments using FT4 and pregnancy-specific reference intervals when available. In children, treatment must be initiated urgently when the diagnosis is made early because the objectives include protection of neurodevelopment and growth. The dose and targets depend on age and clinical context and require frequent monitoring and specialist coordination.
When central hypothyroidism is secondary to a treatable underlying disorder, etiologic treatment may include surgery, radiotherapy, immunosuppression in selected cases of hypophysitis, or targeted treatment of the infiltrative condition. In these settings, thyroid hormone replacement remains necessary to stabilize the patient, whereas the long-term course depends on the natural history of the lesion and the likelihood of recovery of the axis, which should be assessed according to a planned and safe strategy.
Follow-up of central hypothyroidism is intended to ensure effective and safe replacement, prevent undertreatment and overtreatment, and integrate management with surveillance of the underlying hypothalamic-pituitary disorder. The principal biochemical parameter is FT4, which should be reassessed after every dose adjustment and subsequently at regular intervals once a stable equilibrium has been achieved. TSH may be measured but should not independently guide therapeutic decisions. A low TSH may be expected and does not necessarily indicate excess, whereas a TSH within the reference range does not guarantee adequate replacement when FT4 is low or the clinical picture remains consistent with hypothyroidism.
Clinical assessment is essential and should evaluate symptoms compatible with hypothyroidism as well as signs of iatrogenic excess, including palpitations, tremor, insomnia, and unintentional weight loss. In older patients and those with cardiovascular disease, surveillance of cardiovascular symptoms is particularly important and may require a more conservative titration strategy. Follow-up should also assess the lipid profile and other metabolic indicators when clinically relevant, recognizing that correction of thyroid hormone status may produce partial improvements but does not replace comprehensive management of cardiovascular risk factors.
A characteristic component of follow-up in central hypothyroidism is its interaction with other hormonal axes. In patients with hypopituitarism, changes in glucocorticoid replacement, initiation or modification of GH therapy, and management of hypogonadism may influence clinical perception and metabolic balance, requiring periodic and integrated reassessment of thyroid hormone replacement. Management must therefore be coordinated and based on the overall endocrine picture rather than on isolated parameters.
Follow-up must include assessment of adherence and levothyroxine administration because fluctuations in FT4 may result from irregular absorption, interactions with supplements or medications, or dietary changes. Repeated practical review of these factors often reduces the need for dose increases and decreases fluctuations that complicate clinical stabilization.
From an etiologic perspective, follow-up should include surveillance of the sellar or hypothalamic lesion when indicated, using imaging and specialist assessment, and should evaluate the development or progression of deficiencies involving other hormonal axes. This is particularly important after radiotherapy because pituitary dysfunction may progress over time. In patients receiving cancer immunotherapy, coordination with the oncology team is required to distinguish systemic treatment toxicity, cancer progression, and correctable endocrine deficiencies.
When recovery of the axis is possible, reassessment should be planned under controlled conditions and according to clearly defined criteria, avoiding inappropriate treatment withdrawal that could expose the patient to clinically significant hypothyroidism. The decision to reassess depends on the cause, the time elapsed since the initial event, and the stability of the underlying condition. It must form part of a comprehensive plan that considers safety, comorbidities, and the need for treatment continuity.
The prognosis of central hypothyroidism is generally favorable when diagnosis is timely and levothyroxine replacement is prescribed and monitored appropriately using FT4 as the guide. Clinical improvement may be substantial, particularly for fatigue, cold intolerance, and psychomotor slowing, but the response depends on comorbidities and especially on the coexistence of other pituitary hormone deficiencies that may sustain symptoms even after thyroid hormone status has been corrected. Overall prognosis is therefore closely determined by the underlying hypothalamic-pituitary disorder, which may have neurological, ophthalmological, and oncologic implications and may cause progressive endocrine deterioration.
The most common practical complication is undertreatment, often caused by inappropriate use of TSH as the therapeutic target. Persistently low FT4 may sustain dyslipidemia, reduced functional capacity, and cognitive impairment, with consequences for cardiovascular risk and quality of life. In children, undertreatment is particularly important because it may compromise growth and development. Recognition of this complication requires follow-up centered on FT4, the clinical picture, and the overall context, without regarding a TSH within the reference range as reassuring when FT4 remains inadequate.
Conversely, overtreatment is also clinically relevant and may occur when the dose is increased excessively in an attempt to correct a low TSH or when age, cardiovascular disease, and interactions with other therapies are not considered. Iatrogenic thyroid hormone excess increases the risk of atrial fibrillation, tachyarrhythmias, and loss of bone mass, particularly in older individuals and postmenopausal women. Prevention requires appropriate FT4 targets, cautious titration, and careful clinical assessment for signs of iatrogenic hyperthyroidism.
In patients with hypopituitarism, complications may also result from interactions among hormonal axes. Unrecognized or inadequately treated adrenal insufficiency may represent a serious risk when thyroid hormone treatment is initiated or increased without glucocorticoid coverage. This complication is preventable through comprehensive assessment and the correct treatment sequence and is one of the reasons why central hypothyroidism requires structured management.
Complications related to the underlying disease include progression or recurrence of sellar lesions, late effects of radiotherapy, and persistence or recurrence of inflammatory processes. These conditions may cause worsening endocrine dysfunction, require additional treatment, and affect visual and neurological function. In patients with cancer, overall prognosis depends on the oncologic course, but appropriate correction of central hypothyroidism may improve treatment tolerance and reduce events related to unrecognized hormonal deficiency.
Overall, central hypothyroidism can be effectively controlled with appropriate replacement therapy, but it requires specific diagnostic expertise and monitoring because the parameters routinely used in primary hypothyroidism are not applicable and because management must be integrated with the entire hypothalamic-pituitary clinical picture.